An analyst sees good growth prospects for Arcutis Biotherapeutics Inc (ARQT)

With 2.02 million shares changed hands, the volume of the stock remained lighter than its average volume of 5.14 million shares. The 52-week range on ARQT shows that it touched its highest point at $15.40 and its lowest point at $1.76 during that stretch. It currently has a 1-year price target of $18.00. Beta for the stock currently stands at 1.14.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ARQT was up-trending over the past week, with a rise of 1.51%, but this was down by -20.14% over a month. Three-month performance surged to 191.02% while six-month performance rose 77.02%. The stock lost -13.76% in the past year, while it has gained 191.02% so far this year. For the next quarter, that number is -0.74. This implies an EPS growth rate of 34.20% for this year and 40.15% for next year. EPS is expected to grow by 9.80% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -48.07%.

Float and Shares Shorts:

At present, 114.97 million ARQT shares are outstanding with a float of 104.94 million shares on hand for trading. On Mar 15, 2024, short shares totaled 14.99 million, which was 13.04% higher than short shares on Feb 15, 2024. In addition to Mr. Todd Franklin Watanabe M.A. as the firm’s President, CEO & Director, Dr. Bhaskar Chaudhuri Ph.D. serves as its Co-Founder & Independent Director.

Institutional Ownership:

Through their ownership of 96.04% of ARQT’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ARQT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, ARQT has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and ARQT currently yields $0.00. In the past year, ARQT’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, ARQT has a current buyback yield of $–. This was $– for the TTM, and it was $– for the past five years.